The CREDENCE trial was the first RCT to evaluate the effects of the SGLT2 inhibitors on primary kidney outcomes in patients with T2D and macroalbuminuria (i.e., classical diabetic nephropathy) [15]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.